跳轉至內容
Merck
全部照片(1)

重要文件

CDS023093

Sigma-Aldrich

尼洛替尼

同義詞:

4-甲基-3-[[4-(3-吡啶)-2-嘧啶]氨基]-N-[5-(4-甲基-1H-咪唑-1-基)-3-(三氟甲基)苯基]苯甲酰胺, 4-甲基-N-[3-(4-甲基-1H-咪唑-1-基)-5-(三氟甲基)苯基]-3-[[4-(3-吡啶)-2-嘧啶]氨基]苯甲酰胺, 4-甲基-N-[3-(4-甲基咪唑-1-基)-5-三氟甲基苯基]-3-[[4-(吡啶-3-基)嘧啶-2-基]氨基]苯甲酰胺

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C28H22F3N7O
CAS號碼:
分子量::
529.52
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:

描述

AldrichCPR

形狀

solid

儲存溫度

-10 to -25°C

SMILES 字串

CC1=CN(C2=CC(NC(C3=CC=C(C(NC4=NC=CC(C5=CC=CN=C5)=N4)=C3)C)=O)=CC(C(F)(F)F)=C2)C=N1

InChI

1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)

InChI 密鑰

HHZIURLSWUIHRB-UHFFFAOYSA-N

基因資訊

human ... ABL1(25)

一般說明

尼洛替尼(Nilotinib)是氨基嘧啶类衍生物,可用作酪氨酸激酶受体的选择性抑制剂。也可作为抗肿瘤和抗冠状病毒药物。

其他說明

请注意,Sigma-Aldrich将此产品作为一系列独特化学品的一部分提供给早期发现研究人员。Sigma-Aldrich不会收集该产品的分析数据。买方需承担确认产品标识和/或纯度的责任。所有销售均为最终销售。

尽管SIGMA-ALDRICH的标准条款和条件以及SIGMA-ALDRICH′S和买方之间的协议中包含所有合同条款,但无论是在法律、交易过程、执行过程中的行为、以及贸易或其他方面的使用等过程中,SIGMA-ALDRICH按“原样”销售此产品并且并对此产品不作任何陈述或担保,包括:(A)适销性担保;(B)特定用途适用性担保;或(C)未侵犯第三方知识产权担保。

象形圖

Health hazard

訊號詞

Danger

危險聲明

危險分類

Aquatic Chronic 4 - STOT RE 1

標靶器官

Liver,Kidney,gallbladder

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

A Hochhaus et al.
Leukemia, 31(7), 1525-1531 (2017-02-22)
The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., the ability to maintain a molecular response after stopping therapy) following frontline nilotinib treatment. Patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase with MR
Fabienne Lamballe et al.
Oncotarget, 7(46), 74747-74767 (2016-10-13)
The cytoplasmic tyrosine kinase ABL exerts positive or negative effects in solid tumours according to the cellular context, thus functioning as a "switch modulator". The therapeutic effects of drugs targeting a set of signals encompassing ABL have been explored in
Hans Gelderblom et al.
The Lancet. Oncology, 19(5), 639-648 (2018-03-25)
Pigmented villonodular synovitis (alternatively known as diffuse-type giant cell tumour) is a rare, locally aggressive tumour driven by a specific translocation resulting in the overexpression of colony-stimulating factor 1 (CSF1). CSF1 receptor (CSF1R) inhibitors (ie, tyrosine kinase inhibitors and antibodies)
Konstantin Byrgazov et al.
Oncotarget, 7(47), 78083-78094 (2016-11-02)
Point mutations in the ABL1 kinase domain are an important mechanism of resistance to tyrosine kinase inhibitors (TKI) in BCR-ABL1-positive and, as recently shown, BCR-ABL1-like leukemias. The cell line Ba/F3 lentivirally transduced with mutant BCR-ABL1 constructs is widely used for
Hélène Bon et al.
Nephron, 142(4), 328-350 (2019-05-03)
Tubulointerstitial fibrosis is a key feature of chronic kidney diseases leading to renal failure. It is characterised by the infiltration of fibroblasts and aberrant accumulation of extracellular matrix (ECM) proteins, which are associated with progressive loss of renal function. Integrins

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務